Pressure BioSciences, Inc. to Discuss Second Quarter
2016 Financial Results and Provide Business Update
South Easton, MA -- August 15, 2016 -- InvestorsHub
NewsWire -- Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI and
the Company) today announced that the Company will host a
teleconference to discuss its Second Quarter 2016 financial results
and to provide a business update. Anyone interested may listen to
the teleconference either by telephone (live) or through a replay
by telephone or on the Companys website.
The teleconference will include a Company presentation followed
by a question & answer period.
Date: Tuesday, August 16, 2016 Time: 4:30 PM Eastern Daylight
Time (EDT)
To attend this teleconference via telephone:
Dial-in: (877) 407-8031 (North America); (201) 689-8031
(International)
Verbal Passcode (to be given to the operator): Pressure
BioSciences Second Quarter 2016 Financial Call
For those unable to participate in the live teleconference, a
replay will be available beginning on Thursday, August 18, 2016 and
will be accessible both by telephone and through the Companys
website for 30 days.
Replay Number: (877) 660-6853 (North America); (201) 612-7415
(International)
Conference ID Number: 13643814
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) (OTCQB: PBIO) develops,
markets, and sells proprietary laboratory instrumentation and
associated consumables to the estimated $6 billion life sciences
sample preparation market. Our products are based on the unique
properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or PCT) hydrostatic pressure. PCT is a
patented enabling technology platform that uses alternating cycles
of hydrostatic pressure between ambient and ultra-high levels to
safely and reproducibly control bio-molecular interactions. To
date, we have installed nearly 300 PCT systems in approximately 160
sites worldwide. There are over 100 publications citing the
advantages of the PCT platform over competitive methods, many from
key opinion leaders. Our primary development and sales efforts are
in the biomarker discovery, drug discovery and design, and
forensics areas. Customers also use our products in other areas,
such as bio-therapeutics characterization, soil & plant
biology, vaccine development, and counter-bioterror
applications.
For more information about PBI and this press release, please
click on the following link:
http://www.pressurebiosciences.com
Please visit us on Twitter | LinkedIn | YouTube | Google+ | Facebook
Investor Contacts:
Richard T. Schumacher, President & CEO, PBI (T)
508-230-1828